Oppenheimer initiated coverage on Alumis with a new price target
$ALMS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/10/2025 | $18.00 | Buy | Guggenheim |
| 1/30/2025 | $32.00 | Outperform | Oppenheimer |
| 10/31/2024 | $25.00 | Outperform | Robert W. Baird |
| 10/17/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/23/2024 | Overweight | Cantor Fitzgerald | |
| 7/23/2024 | $29.00 | Outperform | Leerink Partners |
| 7/23/2024 | $32.00 | Buy | Guggenheim |
| 7/23/2024 | $36.00 | Overweight | Morgan Stanley |
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the pot
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program of ESK-001 for the treatment of moderate-to-severe plaque psoriasis. "We are excited to announce the completion of patient enrollment in our pivotal Phase 3 ONWARD clinical program evaluating ESK-001 for moderate-to-severe plaque psoriasis," said Martin Babler, President and Chief Executive Officer of Alumis. "With over 1,700 patients enrolled across the two trials, this milestone ref
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. "We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis' differentiated late-stage portfolio and develop transformative th
Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
DEFA14A - ALUMIS INC. (0001847367) (Filer)
DEF 14A - ALUMIS INC. (0001847367) (Filer)
S-8 - ALUMIS INC. (0001847367) (Filer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)